Description
Nootropic Powder Tianeptine New Fast Acting Antidepressant Glyx 13 CAS 117928-94-6
Description
| Product Name: | GLYX 13 | CAS No: | 117928-94-6 |
|---|---|---|---|
| MF: | C18H31N5O6 | MW: | 413.47 |
| Purity: | 98% Min | Shelf Life: | 2 Years |
| Storage: | Cool And Dry Place | Package: | 1KG Per Bag |
| Coa: | Available | ||
| High Light: |
Glyx 13 CAS 117928-94-6, Antidepressant Glyx 13 |
||
Nootropic Powder Tianeptine New Fast-Acting Antidepressant Glyx 13 CAS 117928-94-6
| Product Name | Glyx 13 |
| CAS NO. | 117928-94-6 |
| Appearance | White Powder |
| Purity | 99% or customized |
| COA | Available |
| Usage | Antidepressant |
| Product name: | Glyx-13 |
| CAS: | 117928-94-6 |
| Appearance: | White Powder |
| Purity: | 99% |
Novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder.
Enhance NMDA receptor-mediated signal transduction.
Rapastinel, also known as GLYX-13 and BV-102, is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at the glycine site of the NMDA receptor complex (Emax ≈ 25%).[1][2] The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to both inhibit and enhance NMDA receptor-mediated signal transduction.
Tag:
